updated: 8/27/2012 7:55:38 AM
A federal appeals court has upheld a prior ruling that Indianapolis-based Eli Lilly & Co.'s (NYSE: LLY) compound patent for Alimta is valid. The company now holds patent protection for the cancer drug in the U.S. through January 2017.
August 24, 2012
INDIANAPOLIS, Ind. - Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed a prior ruling by the U.S. District Court for the District of Delaware that the company's compound patent for Alimta (pemetrexed) is valid. The compound patent provides protection for Alimta in the U.S. through January of 2017.
"We are pleased with today's ruling from the Court of Appeals affirming the validity of the compound patent for Alimta," said Robert A. Armitage, senior vice president and general counsel for Lilly. "By affirming the district court ruling, we believe that the Court fairly applied long-standing patent law principles. Protection of intellectual property rights is extremely important to the biopharmaceutical industry and the physicians and patients we serve, as these rights help support the development of the next generation of innovative medicines to treat unmet medical needs."
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.
Source: Eli Lilly and Co.